Cogent Biosciences
Market cap $4.85B 174.0M shares (10-Q, Nov 3, 2026) × $27.85 close Nov 17, 2026
Most recent annual filing: 2026-02-15
- Bezuclastinib commercial launch2H 2026Bezuclastinib commercial launch, 2H 2026, routine
- CGT1815 pan-KRAS Inhibitor IND filing4Q 2026CGT1815 pan-KRAS Inhibitor IND filing, 4Q 2026, notable
- CGT1145 IND filing4Q 2026CGT1145 IND filing, 4Q 2026, notable
- Bezuclastinib + sunitinib GIST PDUFANov 30, 2026Bezuclastinib + sunitinib GIST PDUFA, Nov 30, 2026, thesis-defining
- Bezuclastinib NonAdvSM PDUFA dateDec 30, 2026Bezuclastinib NonAdvSM PDUFA date, Dec 30, 2026, thesis-defining
- 1L exon 9 GIST extension20271L exon 9 GIST extension, 2027, notable
- Bezuclastinib AdvSM PDUFA dateJun 29, 2027Bezuclastinib AdvSM PDUFA date, Jun 29, 2027, thesis-defining
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (7 active programs)
CGT4255
CGT6297
CGT1145
- Undisclosed indication
CGT1815
- Undisclosed indication
Discontinued (1)
- CGT4859 — Cholangiocarcinoma · wind down of the FGFR 2/3 clinical program (10-Q 2026-05-05)
Capital (as filed)
- Cash
- $217M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Short-term investments
- $574M Sep 30, 2026
- Operating cash flow
- −$80.8M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $791M cash, runway late 2028 per the update of Nov 5, 2026 — the company's own words as read there, not the filed figure
Offering documents (1)
- 2026-08-10 424B5 · At-the-market program up to $400M
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (8)
- 2026-11-06 UPDATE: Cogent Biosciences (COGT) - The Hovione Bill Arrives, and the Switch Data Gets a Date 🔒 Paid
- 2026-09-16 UPDATE: Cogent Biosciences (COGT) - The Third Clock Is Set 🔒 Paid
- 2026-09-02 UPDATE: Cogent Biosciences (COGT) - The Silent Killer Gets a Contract 🔒 Paid
- 2026-08-11 UPDATE: Cogent Biosciences (COGT) - The Fortress Gets a Tap, and the Field Team Lands 🔒 Paid
- 2026-06-12 UPDATE: Cogent Biosciences (COGT) - APEX Goes Deep, and the Third Pivotal Lands Clean
- 2026-06-02 UPDATE: Cogent Biosciences (COGT) - PEAK Goes Under the Microscope, and a 1L Shot Opens Up 🔒 Paid
- 2026-05-28 UPDATE: Cogent Biosciences (COGT) - The GIST Clock is Set, ASCO is Saturday 🔒 Paid
- 2026-04-18 Cogent Biosciences (COGT) - Scientific Deep Dive for Bezuclastlnib and Pipeline Products 🔒 Paid
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (8 calls)
Every verdict Biotech Distilled has published on Cogent Biosciences, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2026-04-18 Buy core Cogent Biosciences (COGT) - Scientific Deep Dive for Bezuclastlnib and Pipeline Products Bezuclastinib's best-in-class Type 1 chemistry, CNS-sparing safety profile, $900M fortress balance sheet, and three massive regulatory catalysts in 2026 make it a compelling buy ahead of commercial launch validation.
- 2026-05-28 Buy core UPDATE: Cogent Biosciences (COGT) - The GIST Clock is Set, ASCO is Saturday Priority Review acceptance with November 30 PDUFA for GIST, no AdCom, no review issues, and clean safety data into ASCO oral presentation reinforce the buy thesis ahead of launch validation.
- 2026-06-02 Buy core UPDATE: Cogent Biosciences (COGT) - PEAK Goes Under the Microscope, and a 1L Shot Opens Up ASCO full dataset confirmed topline with a PFS2 durability signal and a new 1L exon 9 cohort adding free optionality, reinforcing the accumulate stance before launch validation prints.
- 2026-06-12 Buy core UPDATE: Cogent Biosciences (COGT) - APEX Goes Deep, and the Third Pivotal Lands Clean APEX ORR upgraded to 65% mIWG with deep molecular responses and imminent AdvSM NDA submission completes the regulatory triple-play, with all three pivotal datasets holding up under scrutiny.
- 2026-08-11 Buy core UPDATE: Cogent Biosciences (COGT) - The Fortress Gets a Tap, and the Field Team Lands Full commercial organization staffed, three NDAs filed, two PDUFAs dated, and pro forma cash of $865.9M covers both launches, though the $400M ATM introduces a real dilution channel and the easy part of the move may be behind us.
- 2026-09-02 Buy core UPDATE: Cogent Biosciences (COGT) - The Silent Killer Gets a Contract Five-year commercial supply agreement with Hovione directly addresses the single-source API bear case, and a 16.8% pullback on no fundamental news restores asymmetry into the November 30 PDUFA.
- 2026-09-16 Buy core UPDATE: Cogent Biosciences (COGT) - The Third Clock Is Set FDA accepted the AdvSM NDA with a June 29, 2027 PDUFA and identical clean language to prior filings, completing three dated regulatory events, though AdvSM appears on standard rather than priority review clock.
- 2026-11-06 Buy core UPDATE: Cogent Biosciences (COGT) - The Hovione Bill Arrives, and the Switch Data Gets a Date Hovione minimum purchase commitments of $108.5M are manageable against $791M cash, pre-launch inventory build signals launch confidence, and ASH switch data lands between the two PDUFAs; down ~30% from August with clinical package intact makes the setup more asymmetric.
- Long call · opened Apr 20, 2026 at $37.00 · -24.7% vs XBI +5.4% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (5 quotes from 4 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“The FDA assigned a Prescription Drug User Fee Act ("PDUFA") target action date of December 30, 2026.”
matched to Bezuclastinib (AdvSM) · regulatory decision
-
-
-
“The FDA assigned a Prescription Drug User Fee Act ("PDUFA") target action date of December 30, 2026.”
matched to Bezuclastinib (AdvSM) · regulatory decision / matched to Bezuclastinib (NonAdvSM) · regulatory decision
-
-
-
“Potential FDA approval of bezuclastinib in GIST – PDUFA date of November 30, 2026”
matched to Bezuclastinib (NonAdvSM) · regulatory decision
-
-
-
“The FDA assigned a Prescription Drug User Fee Act ("PDUFA") target action date of December 30, 2026.”
matched to Bezuclastinib (AdvSM) · regulatory submission / matched to Bezuclastinib (NonAdvSM) · regulatory decision -
“Potential FDA approval of bezuclastinib in GIST – PDUFA date of November 30, 2026”
matched to Bezuclastinib (NonAdvSM) · regulatory decision
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (23)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 5, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 5, 2026ReleaseCogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results→ BD updateSummary on the 8-K
- Nov 5, 20268-KCurrent report: results of operations · EX-99.1→ BD updateWith the GIST PDUFA 25 days out, Cogent's Q3 print shows a commercial build burning fast — G&A tripled to $42.1M in a single quarter — but $791M in cash, $108.5M in locked-in CMO commitments, and a first clinical look at the avapritinib-switch data at ASH keep the thesis intact heading into the most consequential month in the company's history.
- Nov 5, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Oct 27, 2026ReleaseCogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference
- Sep 15, 2026ReleaseCogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)→ BD updateThe FDA accepted Cogent's AdvSM NDA and set a June 29, 2027 PDUFA — completing the regulatory triple-play across all three bezuclastinib indications, with no AdCom and no review issues flagged for the third time in a row.BD extracted 1 program update from this document → COGT pipeline
- Sep 2, 20268-KCurrent report: material agreement→ BD updateCogent just signed a five-year commercial supply agreement with Hovione — the second manufacturer for bezuclastinib drug product — directly retiring the single-source API risk I've called the "silent killer" in every update since May, with 89 days left to the GIST PDUFA.
- Aug 10, 2026ReleaseCogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial ResultsBD extracted 2 program updates from this document → COGT pipeline
- Aug 10, 20268-KCurrent report: other events
- Aug 10, 20268-KCurrent report: results of operations · EX-99.1
- Aug 10, 2026424B5Prospectus supplement (offering)
- Aug 10, 202610-QQuarterly report
- Jun 30, 2026ReleaseCogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)BD extracted 1 program update from this document → COGT pipeline
- Jun 12, 2026ReleaseCogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) CongressBD extracted 1 program update from this document → COGT pipeline
- Jun 12, 2026ReleaseCogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) CongressBD extracted 1 program update from this document → COGT pipeline
- Jun 11, 20268-KCurrent report: shareholder vote
- May 30, 2026ReleaseCogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clini
- May 28, 2026ReleaseCogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST
- May 5, 2026Release- Planning for dual launches of bezuclastinib in Systemic Mastocytosis and Gastrointestinal Stromal Tumors (GIST) - Pivotal data from Phase 3 PEAK trial in GIST patients selected for oral presentation
- May 5, 20268-KCurrent report: results of operations · EX-99.1
- May 5, 202610-QQuarterly report
- Apr 23, 2026DEFA14AProxy soliciting material
- Apr 23, 2026DEF 14AProxy statement
- Mar 31, 2026SCHEDULE 13D/A13D amendment
6 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)
- Aug 13, 2026SCHEDULE 13G/A13G amendment
- Jul 31, 2026SCHEDULE 13GPassive >5% holder (13G)
- Jul 27, 2026SCHEDULE 13G/A13G amendment
- May 14, 2026SCHEDULE 13G/A13G amendment
- Apr 23, 2026ARSAnnual report to shareholders
- Mar 26, 2026SCHEDULE 13G/A13G amendment